Article type: Review Article
Article
title: Buspirone-associated movement disorder: a literature review
Journal: Prague
Medical Report
Year: 2020
Authors: Jamir Pitton Rissardo, Ana Letícia Fornari
Caprara
E-mail: jamirrissardo@gmail.com
ABSTRACT
Buspirone
(BUS) belongs to the azapirone chemical class. The aim of this literature
review is to evaluate the clinical epidemiological profile, pathological
mechanisms, and management of BUS-associated movement disorders (MD). Relevant
reports in six databases were identified and assessed by two reviewers without
language restriction. A total of 25 reports containing 65 cases were assessed.
The MD associated with BUS were: dyskinesia in 14 cases, 10 of akathisia, 8 of
myoclonus, 6 of Parkinsonism, and 6 of dystonia. The cases not clearly defined
were 7 tension, 14 incoordination, and the undefined number of dyskinesia,
tics, and Parkinsonism. The mean age was 45.23 years (range: 15–74). The male
was the predominant sex in 60.86% and the most common BUS-indication was
anxiety disorder. The mean BUS-dose was 42.16 mg (range: 5–100). The time from
the beginning of BUS administration to the MD onset was one month or less in
76%. The time from BUS withdrawal to complete recovery was within one month in
87.5%. The most common management was BUS withdrawal. In 16 patients the
follow-up was reported: 14 had a full recovery, but in two (1 dyskinesia + 1
dystonia) the symptoms continued after the BUS withdrawal. MD associated with
BUS were scarcely reported in the literature. Moreover, in the majority of
cases, no clear description of the clinical profile, neurological examination,
or the time data of the movement disorder onset and recovery were given.
Keywords: Buspirone, mj 9022-1, review, movement
disorder, drug-induced
Full text available at:
https://pmr.lf1.cuni.cz/121/1/0005/
DOI
10.14712/23362936.2020.1
Citation
Rissardo JP, Caprara AL. Buspirone-associated movement disorder: a literature review. Prague Med Rep 2020;121:5-24
